Acute effects of 5-methyltetrahydrofolate on endothelial function and asymmetric dimethylarginine in patients with chronic heart failure

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 20, Issue 5, 2010, Pages 341-349

  Paul, B ^a   Whiting, M J ^a   De Pasquale, C G ^a   Mangoni, A A ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

5 Methyltetrahydrofolate; Asymmetric dimethylarginine; Chronic heart failure; Endothelial function; Nitric oxide

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; 5-METHYLTETRAHYDROFOLATE; ARGININE; DRUG DERIVATIVE; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE; TETRAHYDROFOLIC ACID DERIVATIVE;

AGED; ARTICLE; BLOOD; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM;

AGED; ARGININE; CHRONIC DISEASE; ENDOTHELIUM, VASCULAR; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; TETRAHYDROFOLATES;

EID: 77956656832     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2009.04.008     Document Type: Article

References (45)

1. Mangoni A.A., Sherwood R.A., Asonganyi B., Swift C.G., Thomas S., Jackson S.H. Short-term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes. Am J Hypertens 2005, 18:220-226.
2. van Etten R.W., de Koning E.J., Verhaar M.C., Gaillard C.A., Rabelink T.J. Impaired NO-dependent vasodilation in patients with Type II (non-insulin-dependent) diabetes mellitus is restored by acute administration of folate. Diabetologia 2002, 45:1004-1010.
3. Mangoni A.A., Sherwood R.A., Swift C.G., Jackson S.H. Folic acid enhances endothelial function and reduces blood pressure in smokers: a randomized controlled trial. J Intern Med 2002, 252:497-503.
4. Doshi S.N., McDowell I.F., Moat S.J., Payne N., Durrant H.J., Lewis M.J., et al. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 2002, 105:22-26.
5. Verhaar M.C., Wever R.M., Kastelein J.J., van Dam T., Koomans H.A., Rabelink T.J. 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 1998, 97:237-241.
6. Hyndman M.E., Verma S., Rosenfeld R.J., Anderson T.J., Parsons H.G. Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. Am J Physiol Heart Circ Physiol 2002, 282:H2167-H2172.
7. Stroes E.S., van Faassen E.E., Yo M., Martasek P., Boer P., Govers R., et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2000, 86:1129-1134.
8. Katz S.D., Schwarz M., Yuen J., LeJemtel T.H. Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure. Role of endothelium-derived vasodilating and vasoconstricting factors. Circulation 1993, 88:55-61.
9. Takahashi K., Ohyanagi M., Ikeoka K., Ueda A., Koida S. Variations of endothelium-dependent vasoresponses in congestive heart failure. J Cardiovasc Pharmacol 2005, 45:14-21.
10. Hare J.M., Nguyen G.C., Massaro A.F., Drazen J.M., Stevenson L.W., Colucci W.S., et al. Exhaled nitric oxide: a marker of pulmonary hemodynamics in heart failure. J Am Coll Cardiol 2002, 40:1114-1119.
11. Abassi Z.A., Gurbanov K., Mulroney S.E., Potlog C., Opgenorth T.J., Hoffman A., et al. Impaired nitric oxide-mediated renal vasodilation in rats with experimental heart failure: role of angiotensin II. Circulation 1997, 96:3655-3664.
12. Kielstein J.T., Bode-Boger S.M., Klein G., Graf S., Haller H., Fliser D. Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure. Eur J Clin Invest 2003, 33:370-375.
13. Usui M., Matsuoka H., Miyazaki H., Ueda S., Okuda S., Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 1998, 62:2425-2430.
14. Duckelmann C., Mittermayer F., Haider D.G., Altenberger J., Eichinger J., Wolzt M. Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler Thromb Vasc Biol 2007, 27:2037-2042.
15. Gonzalez M.A., Selwyn A.P. Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med 2003, 115(Suppl. 8A):99S-106S.
16. Katz S.D., Hryniewicz K., Hriljac I., Balidemaj K., Dimayuga C., Hudaihed A., et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 2005, 111:310-314.
17. Bell D.M., Johns T.E., Lopez L.M. Endothelial dysfunction: implications for therapy of cardiovascular diseases. Ann Pharmacother 1998, 32:459-470.
18. Ignarro L.J., Napoli C. Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis. Curr Atheroscler Rep 2004, 6:281-287.
19. Alp N.J., Channon K.M. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol 2004, 24:413-420.
20. Palm F., Onozato M.L., Luo Z., Wilcox C.S. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol 2007, 293:H3227-H3245.
21. Mangoni A.A., Jackson S.H. Homocysteine and cardiovascular disease: current evidence and future prospects. Am J Med 2002, 112:556-565.
22. Antoniades C., Shirodaria C., Warrick N., Cai S., de Bono J., Lee J., et al. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006, 114:1193-1201.
23. McKee P.A., Castelli W.P., McNamara P.M., Kannel W.B. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971, 285:1441-1446.
24. Anumba D.O., Robson S.C., Boys R.J., Ford G.A. Nitric oxide activity in the peripheral vasculature during normotensive and preeclamptic pregnancy. Am J Physiol 1999, 277:H848-H854.
25. O'Rourke M.F., Pauca A., Jiang X.J. Pulse wave analysis. Br J Clin Pharmacol 2001, 51:507-522.
26. Wilkinson I.B., Hall I.R., MacCallum H., Mackenzie I.S., McEniery C.M., van der Arend B.J., et al. Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function. Arterioscler Thromb Vasc Biol 2002, 22:147-152.
27. Papaioannou T.G., Karatzis E.N., Karatzi K.N., Gialafos E.J., Protogerou A.D., Stamatelopoulos K.S., et al. Hour-to-hour and week-to-week variability and reproducibility of wave reflection indices derived by aortic pulse wave analysis: implications for studies with repeated measurements. J Hypertens 2007, 25:1678-1686.
28. Ubbink J.B., Hayward Vermaak W.J., Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 1991, 565:441-446.
29. Schwedhelm E., Tan-Andresen J., Maas R., Riederer U., Schulze F., Boger R.H. Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem 2005, 51:1268-1271.
30. Andersson S.E., Edvinsson M.L., Edvinsson L. Reduction of homocysteine in elderly with heart failure improved vascular function and blood pressure control but did not affect inflammatory activity. Basic Clin Pharmacol Toxicol 2005, 97:306-310.
31. Fischer D., Rossa S., Landmesser U., Spiekermann S., Engberding N., Hornig B., et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J 2005, 26:65-69.
32. Heitzer T., Baldus S., von Kodolitsch Y., Rudolph V., Meinertz T. Systemic endothelial dysfunction as an early predictor of adverse outcome in heart failure. Arterioscler Thromb Vasc Biol 2005, 25:1174-1179.
33. Dixon L.J., Morgan D.R., Hughes S.M., McGrath L.T., El Sherbeeny N.A., Plumb R.D., et al. Functional consequences of endothelial nitric oxide synthase uncoupling in congestive cardiac failure. Circulation 2003, 107:1725-1728.
34. Tousoulis D., Charakida M., Stefanadis C. Inflammation and endothelial dysfunction as therapeutic targets in patients with heart failure. Int J Cardiol 2005, 100:347-353.
35. Bauersachs J., Schafer A. Endothelial dysfunction in heart failure: mechanisms and therapeutic approaches. Curr Vasc Pharmacol 2004, 2:115-124.
36. Rambaran C., Jiang B., Ritter J.M., Shah A., Kalra L., Chowienczyk P.J. Assessment of endothelial function: comparison of the pulse wave response to beta 2-adrenoceptor stimulation with flow mediated dilatation. Br J Clin Pharmacol 2008, 65:238-243.
37. Bank A.J., Lee P.C., Kubo S.H. Endothelial dysfunction in patients with heart failure: relationship to disease severity. J Card Fail 2000, 6:29-36.
38. Poelzl G., Frick M., Huegel H., Lackner B., Alber H.F., Mair J., et al. Chronic heart failure is associated with vascular remodeling of the brachial artery. Eur J Heart Fail 2005, 7:43-48.
39. Taylor A.L. Endothelial dysfunction and nitric oxide enhancing therapy: a new approach to the treatment of heart failure. Congest Heart Fail 2004, 10:237-242.
40. Herrmann W., Obeid R. Hyperhomocysteinemia and response of methionine cycle intermediates to vitamin treatment in renal patients. Clin Chem Lab Med 2005, 43:1039-1047.
41. Holven K.B., Haugstad T.S., Holm T., Aukrust P., Ose L., Nenseter M.S. Folic acid treatment reduces elevated plasma levels of asymmetric dimethylarginine in hyperhomocysteinaemic subjects. Br J Nutr 2003, 89:359-363.
42. Spoelstra-de Man A.M., Teerlink T., Brouwer C.B., Rauwerda J.A., Stehouwer C.D., Smulders Y.M. No effect of B vitamins on ADMA levels in patients at increased cardiovascular risk. Clin Endocrinol (Oxf) 2006, 64:495-501.
43. Sydow K., Schwedhelm E., Arakawa N., Bode-Boger S.M., Tsikas D., Hornig B., et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of l-arginine and B vitamins. Cardiovasc Res 2003, 57:244-252.
44. Ziegler S., Mittermayer F., Plank C., Minar E., Wolzt M., Schernthaner G.H. Homocyst(e)ine-lowering therapy does not affect plasma asymmetrical dimethylarginine concentrations in patients with peripheral artery disease. J Clin Endocrinol Metab 2005, 90:2175-2178.
45. Chen Y., Li Y., Zhang P., Traverse J.H., Hou M., Xu X., et al. Dimethylarginine dimethylaminohydrolase and endothelial dysfunction in failing hearts. Am J Physiol Heart Circ Physiol 2005, 289:H2212-H2219.